Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Perspectives on CML management

    from Professor Jerry Radich
    Fred Hutchinson Cancer Research Center
    Seattle, USA

    • Assessment of existing therapies in CML including new data on bosunitib in front-line therapy
    • Emerging new therapies for CML and how they could come into practice
    • Perspectives on treatment discontinuation
    • Challenges of CML management in the emerging economic regions: access to treatment and testing


    {rscomments off}